5gs0: Difference between revisions

No edit summary
No edit summary
Tag: Manual revert
 
(2 intermediate revisions by the same user not shown)
Line 3: Line 3:
<StructureSection load='5gs0' size='340' side='right'caption='[[5gs0]], [[Resolution|resolution]] 3.27&Aring;' scene=''>
<StructureSection load='5gs0' size='340' side='right'caption='[[5gs0]], [[Resolution|resolution]] 3.27&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[5gs0]] is a 10 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5GS0 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5GS0 FirstGlance]. <br>
<table><tr><td colspan='2'>[[5gs0]] is a 10 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5GS0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5GS0 FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.275&#8491;</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5gru|5gru]], [[5grv|5grv]], [[5grw|5grw]], [[5grx|5grx]], [[5gry|5gry]], [[5grz|5grz]], [[5gs1|5gs1]], [[5gs2|5gs2]], [[5gs3|5gs3]]</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">TLR3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5gs0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5gs0 OCA], [https://pdbe.org/5gs0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5gs0 RCSB], [https://www.ebi.ac.uk/pdbsum/5gs0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5gs0 ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5gs0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5gs0 OCA], [http://pdbe.org/5gs0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5gs0 RCSB], [http://www.ebi.ac.uk/pdbsum/5gs0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5gs0 ProSAT]</span></td></tr>
</table>
</table>
== Disease ==
== Disease ==
[[http://www.uniprot.org/uniprot/TLR3_HUMAN TLR3_HUMAN]] Defects in TLR3 are associated with herpes simplex encephalitis type 2 (HSE2) [MIM:[http://omim.org/entry/613002 613002]]. HSE is a rare complication of human herpesvirus 1 (HHV-1) infection, occurring in only a small minority of HHV-1 infected individuals. HSE is characterized by hemorrhagic necrosis of parts of the temporal and frontal lobes. Onset is over several days and involves fever, headache, seizures, stupor, and often coma, frequently with a fatal outcome. Note=TLR3 mutations predispose otherwise healthy individuals to isolated herpes simplex encephalitis through a mechanism that involves impaired IFNs production and reduced immune defense against viral infection in the central nervous system.<ref>PMID:17872438</ref>
[https://www.uniprot.org/uniprot/TLR3_HUMAN TLR3_HUMAN] Defects in TLR3 are associated with herpes simplex encephalitis type 2 (HSE2) [MIM:[https://omim.org/entry/613002 613002]. HSE is a rare complication of human herpesvirus 1 (HHV-1) infection, occurring in only a small minority of HHV-1 infected individuals. HSE is characterized by hemorrhagic necrosis of parts of the temporal and frontal lobes. Onset is over several days and involves fever, headache, seizures, stupor, and often coma, frequently with a fatal outcome. Note=TLR3 mutations predispose otherwise healthy individuals to isolated herpes simplex encephalitis through a mechanism that involves impaired IFNs production and reduced immune defense against viral infection in the central nervous system.<ref>PMID:17872438</ref>  
== Function ==
== Function ==
[[http://www.uniprot.org/uniprot/TLR3_HUMAN TLR3_HUMAN]] Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.<ref>PMID:16144834</ref> <ref>PMID:16858407</ref> <ref>PMID:16720699</ref> <ref>PMID:17178723</ref> <ref>PMID:18172197</ref> <ref>PMID:16043704</ref>
[https://www.uniprot.org/uniprot/TLR3_HUMAN TLR3_HUMAN] Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.<ref>PMID:16144834</ref> <ref>PMID:16858407</ref> <ref>PMID:16720699</ref> <ref>PMID:17178723</ref> <ref>PMID:18172197</ref> <ref>PMID:16043704</ref>  
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 24: Line 23:


==See Also==
==See Also==
*[[Antibody 3D structures|Antibody 3D structures]]
*[[Toll-like Receptor 3D structures|Toll-like Receptor 3D structures]]
*[[Toll-like Receptor 3D structures|Toll-like Receptor 3D structures]]
== References ==
== References ==
Line 29: Line 29:
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Human]]
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Large Structures]]
[[Category: Lk3 transgenic mice]]
[[Category: Mus musculus]]
[[Category: Cho, G]]
[[Category: Cho G]]
[[Category: Kim, J H]]
[[Category: Kim JH]]
[[Category: Kim, J W]]
[[Category: Kim JW]]
[[Category: Lee, H]]
[[Category: Lee H]]
[[Category: Lee, J O]]
[[Category: Lee JO]]
[[Category: Song, D H]]
[[Category: Song DH]]
[[Category: Youn, S J]]
[[Category: Youn SJ]]
[[Category: Antibody fragment]]
[[Category: Complex]]
[[Category: Diabody]]
[[Category: Immune system]]

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA